
{
  "Company Overview": {
    "Name": "Jagsonpal Pharmaceuticals Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Manufactures and trades pharmaceutical products and active pharmaceutical ingredients.  Focuses on women-specific healthcare needs through Gynaecology and Orthopaedics. Also present in antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics.",
    "Market Position": "17 brands amongst Top 5 brands in the molecule category. Pan-India presence through 900+ sales individuals. ~47% of FY24 revenue from top 5 brands, ~67% from top 7 brands."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 1,746 Cr.",
    "Current Price": "₹ 658",
    "High/Low": "₹ 820 / ₹ 270",
    "P/E Ratio": 65.2,
    "Book Value": "₹ 74.4",
    "Dividend Yield": "0.76%",
    "ROCE": "17.0%",
    "ROE": "13.0%",
    "Face Value": "₹ 5.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further analysis from Balance Sheet data.
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [59, 54, 51, 61, 61, 60, 55, 60, 58, 47, 43, 61, 75],
      "Expenses": [50, 49, 50, 53, 48, 52, 50, 52, 49, 44, 41, 51, 58],
      "Operating Profit": [9, 6, 1, 7, 13, 9, 5, 9, 8, 3, 3, 10, 16],
      "OPM %": ["16%", "10%", "2%", "12%", "21%", "14%", "10%", "14%", "14%", "7%", "6%", "17%", "22%"],
      "Other Income": [0, 2, 0, -3, 1, 2, 3, 2, 2, 3, 2, -2, 2],
      "Interest": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],
      "Depreciation": [0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 2],
      "Profit before tax": [9, 7, 0, 4, 14, 10, 7, 10, 10, 5, 5, 7, 15],
      "Tax %": ["30%", "24%", "32%", "24%", "24%", "21%", "24%", "26%", "25%", "25%", "22%", "25%", "25%"],
      "Net Profit": [7, 5, 0, 3, 10, 8, 6, 7, 7, 4, 4, 5, 11],
      "EPS in Rs": [2.50, 2.07, 0.12, 1.11, 3.97, 2.97, 2.14, 2.86, 2.85, 1.51, 1.34, 2.01, 4.33]
    },
    "Annual Results": {
      "Sales": [166, 144, 138, 143, 144, 127, 167, 159, 188, 218, 237, 209, 227],
      "Expenses": [156, 133, 129, 132, 138, 138, 157, 150, 169, 192, 203, 186, 194],
      "Operating Profit": [10, 11, 9, 12, 6, -11, 9, 9, 19, 26, 34, 23, 33],
      "OPM %": ["6%", "7%", "6%", "8%", "4%", "-9%", "6%", "5%", "10%", "12%", "14%", "11%", "14%"],
      "Other Income": [0, 0, 0, 1, 13, 0, 1, 3, 4, 3, 2, 9, 5],
      "Interest": [5, 5, 4, 5, 3, 1, 1, 1, 1, 0, 0, 1, 1],
      "Depreciation": [3, 3, 3, 3, 2, 0, 1, 1, 1, 2, 1, 2, 4],
      "Profit before tax": [3, 3, 2, 4, 14, -12, 9, 9, 22, 27, 35, 30, 32],
      "Tax %": ["28%", "16%", "30%", "20%", "18%", "-1%", "20%", "16%", "22%", "29%", "23%", "25%", "25%"],
      "Net Profit": [2, 2, 1, 3, 12, -12, 7, 8, 17, 19, 27, 22, 24],
      "EPS in Rs": [0.70, 0.81, 0.45, 1.24, 4.53, -4.41, 2.76, 3.00, 6.51, 7.20, 10.20, 8.50, 9.19]
    },
    "Sales Growth": {
      "10 Years": "4%",
      "5 Years": "5%",
      "3 Years": "4%",
      "TTM": "-3%"
    },
    "Profit Growth": {
      "10 Years": "27%",
      "5 Years": "25%",
      "3 Years": "10%",
      "TTM": "-6%"
    },
    "Stock Price CAGR": {
      "10 Years": "34%",
      "5 Years": "92%",
      "3 Years": "60%",
      "1 Year": "69%"
    }
  },
  "Ratios": {
    "Debtor Days": [93, 115, 119, 106, 100, 73, 45, 49, 25, 26, 32, 19],
    "Inventory Days": [127, 173, 176, 246, 295, 307, 164, 191, 134, 122, 82, 68],
    "Days Payable": [28, 29, 42, 60, 56, 54, 59, 76, 82, 76, 66, 35],
    "Cash Conversion Cycle": [192, 259, 252, 292, 339, 325, 150, 164, 77, 72, 48, 53],
    "Working Capital Days": [130, 155, 171, 169, 174, 173, 76, 66, 45, 59, 36, 59],
    "ROCE %": ["6%", "6%", "5%", "7%", "3%", "-10%", "9%", "9%", "18%", "20%", "25%", "17%"]
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10}
    ],
    "Median": {
      "CMP": 512.7,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is almost debt free.",
      "Company has been maintaining a healthy dividend payout of 54.5%",
      "Debtor days have improved from 25.8 to 19.2 days."
    ],
    "Cons": [
      "Stock is trading at 8.84 times its book value",
      "The company has delivered a poor sales growth of 4.58% over past five years."
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes."
  },
  "BalanceSheet": {
    "Equity Capital": [13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13],
    "Reserves": [85, 85, 82, 85, 97, 85, 91, 98, 109, 120, 146, 174, 184],
    "Borrowings": [33, 36, 39, 38, 8, 8, 4, 5, 7, 0, 6, 9, 10],
    "Other Liabilities": [21, 22, 19, 22, 25, 23, 28, 31, 35, 31, 30, 21, 51],
    "Total Liabilities": [153, 156, 154, 159, 143, 130, 136, 147, 164, 164, 195, 217, 258],
    "Fixed Assets": [58, 56, 52, 52, 22, 21, 22, 22, 26, 23, 24, 9, 99],
    "CWIP": [2, 2, 0, 0, 0, 3, 4, 4, 0, 0, 0, 0, 0],
    "Investments": [0, 0, 0, 0, 0, 0, 0, 11, 15, 51, 1, 0, 0],
    "Other Assets": [92, 98, 102, 108, 121, 105, 110, 109, 123, 91, 170, 208, 159],
    "Total Assets": [153, 156, 154, 159, 143, 130, 136, 147, 164, 164, 195, 217, 258]
  },
  "CashFlow": {
    "Cash from Operating Activity": [12, 8, 4, 9, -3, -2, 31, 11, 28, 7, 47, 35],
    "Cash from Investing Activity": [-3, -1, 0, -2, 41, -3, -1, -11, -2, -26, -58, -25],
    "Cash from Financing Activity": [-8, -4, -1, -6, -34, -1, -6, -1, -7, -18, 0, -9],
    "Net Cash Flow": [0, 2, 2, 1, 5, -6, 24, 0, 19, -36, -11, 2]
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [70.34, 68.71, 68.71, 68.72, 68.72, 68.72, 68.72, 68.72, 68.48, 68.09, 68.04, 67.98],
      "FIIs": [0.20, 0.00, 0.00, 0.13, 0.11, 0.10, 0.37, 0.38, 0.53, 0.73, 1.10, 2.30],
      "DIIs": [0.00, 0.67, 0.68, 0.28, 0.77, 0.82, 0.82, 0.82, 0.82, 0.84, 0.84, 0.11],
      "Public": [29.46, 30.61, 30.61, 30.85, 30.40, 30.34, 30.07, 30.07, 30.16, 30.33, 30.01, 29.63]
    },
    "Yearly": {
      "Promoters": [69.17, 69.17, 69.17, 70.26, 70.34, 70.34, 68.71, 68.72, 68.09, 67.98],
      "FIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.10, 0.73, 2.30],
      "DIIs": [0.00, 0.00, 0.00, 0.00, 0.01, 0.00, 0.67, 0.82, 0.84, 0.11],
      "Public": [30.83, 30.83, 30.83, 29.74, 29.66, 29.65, 30.61, 30.34, 30.33, 29.63]
    },
    "No. of Shareholders": [20031, 17100, 16194, 14952, 14535, 14084, 13782, 16041, 15785, 16282, 15748, 15633]
  },
  "Documents": {
    "Announcements": [
      {"Title": "Intimation For Record Date For Sub- Division/Split Of Equity Shares Of The Company", "Date": "17 Dec"},
      {"Title": "Shareholder Meeting / Postal Ballot-Scrutinizer's Report", "Date": "12 Dec"},
      {"Title": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS", "Date": "6 Dec"},
      {"Title": "Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)", "Date": "22 Nov"},
      {"Title": "Update On Intimation As Per Regulation 30 Of SEBI (LODR) Regulations, 2015 - Sale Of Company's Faridabad Facility", "Date": "19 Nov"}
    ],
    "Annual Reports": [
      {"Year": 2024, "Source": "bse"},
      {"Year": 2023, "Source": "bse"},
      {"Year": 2022, "Source": "bse"},
      {"Year": 2021, "Source": "bse"},
      {"Year": 2020, "Source": "bse"},
      {"Year": 2019, "Source": "bse"},
      {"Year": 2018, "Source": "bse"},
      {"Year": 2017, "Source": "bse"},
      {"Year": 2016, "Source": "bse"},
      {"Year": 2015, "Source": "bse"},
      {"Year": 2014, "Source": "bse"},
      {"Year": 2013, "Source": "bse"},
      {"Year": 2012, "Source": "bse"},
      {"Year": 2011, "Source": "nse"},
      {"Year": 2010, "Source": "nse"}
    ],
    "Credit Ratings": [
      {"Date": "21 Jun", "Source": "icra"},
      {"Date": "14 Apr 2023", "Source": "icra"},
      {"Date": "10 Oct 2022", "Source": "icra"},
      {"Date": "10 Mar 2022", "Source": "icra"},
      {"Date": "4 Mar 2021", "Source": "icra"},
      {"Date": "19 Aug 2020", "Source": "icra"}
    ],
    "Concalls": [
      {"Date": "Oct 2024"},
      {"Date": "Aug 2024"},
      {"Date": "May 2024"},
      {"Date": "Feb 2024"},
      {"Date": "Nov 2023"},
      {"Date": "May 2023"},
      {"Date": "Feb 2023"},
      {"Date": "Feb 2022"}
    ]
  }
}
